• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13D filed by Eikon Therapeutics Inc.

    2/12/26 6:48:54 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $EIKN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    Eikon Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)


    86889P208

    (CUSIP Number)


    James Evangelista, CFO
    The Column Group III, LP, 1 Letterman Drive, Building D
    San Francisco, CA, 94129
    (415) 865-2050

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    02/06/2026

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    86889P208


    1 Name of reporting person

    The Column Group IV GP, LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    4,460,979.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    4,460,979.00
    11Aggregate amount beneficially owned by each reporting person

    4,460,979.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    8.3 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    Consists of (i) 4,312,139 shares of Common Stock held of record by TCG IV LP (as defined in Item 2(a) below) and (ii) 148,840 shares of Common Stock held of record by TCG IV-A LP (as defined in Item 2(a) below). TCG IV GP LP (as defined in Item 2(a) below) is the general partner of each of TCG IV LP and TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to these securities. This calculation is based upon 53,984,337 shares of Common Stock outstanding (assuming the underwriters do not exercise their option to purchase additional shares) as reported by the Issuer in its prospectus filed with the Securities and Exchange Commission on February 5, 2026 (the Prospectus).


    SCHEDULE 13D

    CUSIP No.
    86889P208


    1 Name of reporting person

    The Column Group IV, LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    4,312,139.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    4,312,139.00
    11Aggregate amount beneficially owned by each reporting person

    4,312,139.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    8.0 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    Consists of 4,312,139 shares of Common Stock held of record by TCG IV LP. TCG IV GP LP is the general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to these securities. This calculation is based upon 53,984,337 shares of Common Stock outstanding (assuming the underwriters do not exercise their option to purchase additional shares) as reported in the Prospectus.


    SCHEDULE 13D

    CUSIP No.
    86889P208


    1 Name of reporting person

    The Column Group IV-A, LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    148,840.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    148,840.00
    11Aggregate amount beneficially owned by each reporting person

    148,840.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0.3 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    Consists of 148,840 shares of Common Stock held of record by TCG IV-A LP. TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to these securities. This calculation is based upon 53,984,337 shares of Common Stock outstanding (assuming the underwriters do not exercise their option to purchase additional shares) as reported in the Prospectus.


    SCHEDULE 13D

    CUSIP No.
    86889P208


    1 Name of reporting person

    The Column Group Opportunity III, LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,892,733.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,892,733.00
    11Aggregate amount beneficially owned by each reporting person

    1,892,733.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    3.5 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    Consists of (i) 1,319,164 shares of Common Stock held of record by TCG Opportunity III LP (as defined in Item 2(a)) and (ii) 573,569 shares underlying warrants to purchase shares of Common Stock held by TCG Opportunity III LP which are exercisable within 60 days of this Statement. TCG Opportunity III GP LP (as defined in Item 2(a)) is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP LLC (as defined in Item 2(a)) is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson and Tim Kutzkey are the managing members of TCG Opportunity III GP LLC and may each be deemed to share voting, investment and dispositive power with respect to these securities. This calculation is based upon 54,557,906 shares of Common Stock, which is the sum of (i) 53,984,337 shares of Common Stock outstanding (assuming the underwriters do not exercise their option to purchase additional shares) as reported in the Prospectus, plus (ii) 573,569 shares underlying warrants to purchase shares of Common Stock held by TCG Opportunity III LP which are exercisable within 60 days of this Statement.


    SCHEDULE 13D

    CUSIP No.
    86889P208


    1 Name of reporting person

    The Column Group Opportunity III GP, LP
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,892,733.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,892,733.00
    11Aggregate amount beneficially owned by each reporting person

    1,892,733.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    3.5 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    Consists of (i) 1,319,164 shares of Common Stock held of record by TCG Opportunity III LP and (ii) 573,569 shares underlying warrants to purchase shares of Common Stock held by TCG Opportunity III LP which are exercisable within 60 days of this Statement. TCG Opportunity III GP LP is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson and Tim Kutzkey are the managing members of TCG Opportunity III GP LLC and may each be deemed to share voting, investment and dispositive power with respect to these securities. This calculation is based upon 54,557,906 shares of Common Stock, which is the sum of (i) 53,984,337 shares of Common Stock outstanding (assuming the underwriters do not exercise their option to purchase additional shares) as reported in the Prospectus, plus (ii) 573,569 shares underlying warrants to purchase shares of Common Stock held by TCG Opportunity III LP which are exercisable within 60 days of this Statement.


    SCHEDULE 13D

    CUSIP No.
    86889P208


    1 Name of reporting person

    TCG Opportunity III GP, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    1,892,733.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    1,892,733.00
    11Aggregate amount beneficially owned by each reporting person

    1,892,733.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    3.5 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    Consists of (i) 1,319,164 shares of Common Stock held of record by TCG Opportunity III LP and (ii) 573,569 shares underlying warrants to purchase shares of Common Stock held by TCG Opportunity III LP which are exercisable within 60 days of this Statement. TCG Opportunity III GP LP is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson and Tim Kutzkey are the managing members of TCG Opportunity III GP LLC and may each be deemed to share voting, investment and dispositive power with respect to these securities. This calculation is based upon 54,557,906 shares of Common Stock, which is the sum of (i) 53,984,337 shares of Common Stock outstanding (assuming the underwriters do not exercise their option to purchase additional shares) as reported in the Prospectus, plus (ii) 573,569 shares underlying warrants to purchase shares of Common Stock held by TCG Opportunity III LP which are exercisable within 60 days of this Statement.


    SCHEDULE 13D

    CUSIP No.
    86889P208


    1 Name of reporting person

    Tim Kutzkey
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    6,353,712.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    6,353,712.00
    11Aggregate amount beneficially owned by each reporting person

    6,353,712.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    11.6 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    Consists of (i) 4,312,139 shares of Common Stock held of record by TCG IV LP, (ii) 148,840 shares of Common Stock held of record by TCG IV-A LP, (iii) 1,319,164 shares of Common Stock held of record by TCG Opportunity III LP and (iv) 573,569 shares underlying warrants to purchase shares of Common Stock held by TCG Opportunity III LP which are exercisable within 60 days of this Statement. TCG IV GP LP is the general partner of each of TCG IV LP and TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson and Tim Kutzkey are the managing members of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP LP is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson and Tim Kutzkey are the managing members of TCG Opportunity III GP LLC and may each be deemed to share voting, investment and dispositive power with respect to these securities. This calculation is based upon 54,557,906 shares of Common Stock, which is the sum of (i) 53,984,337 shares of Common Stock outstanding (assuming the underwriters do not exercise their option to purchase additional shares) as reported in the Prospectus, plus (ii) 573,569 shares underlying warrants to purchase shares of Common Stock held by TCG Opportunity III LP which are exercisable within 60 days of this Statement.


    SCHEDULE 13D

    CUSIP No.
    86889P208


    1 Name of reporting person

    Peter Svennilson
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    SWEDEN
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    6,353,712.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    6,353,712.00
    11Aggregate amount beneficially owned by each reporting person

    6,353,712.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    11.6 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    Consists of (i) 4,312,139 shares of Common Stock held of record by TCG IV LP, (ii) 148,840 shares of Common Stock held of record by TCG IV-A LP, (iii) 1,319,164 shares of Common Stock held of record by TCG Opportunity III LP and (iv) 573,569 shares underlying warrants to purchase shares of Common Stock held by TCG Opportunity III LP which are exercisable within 60 days of this Statement. TCG IV GP LP is the general partner of each of TCG IV LP and TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson and Tim Kutzkey are the managing members of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP LP is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. Peter Svennilson and Tim Kutzkey are the managing members of TCG Opportunity III GP LLC and may each be deemed to share voting, investment and dispositive power with respect to these securities. This calculation is based upon 54,557,906 shares of Common Stock, which is the sum of (i) 53,984,337 shares of Common Stock outstanding (assuming the underwriters do not exercise their option to purchase additional shares) as reported in the Prospectus, plus (ii) 573,569 shares underlying warrants to purchase shares of Common Stock held by TCG Opportunity III LP which are exercisable within 60 days of this Statement.


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, $0.0001 par value per share
    (b)Name of Issuer:

    Eikon Therapeutics, Inc.
    (c)Address of Issuer's Principal Executive Offices:

    230 Harriet Tubman Way, Millbrae, CALIFORNIA , 94030.
    Item 2.Identity and Background
    (a)
    This Statement is being filed by The Column Group IV, LP (TCG IV LP), The Column Group IV-A, LP (TCG IV-A LP), The Column Group IV GP, LP (TCG IV GP LP), The Column Group Opportunity III, LP (TCG Opportunity III LP), The Column Group Opportunity III GP, LP (TCG Opportunity III GP LP), TCG Opportunity III GP, LLC (TCG Opportunity III GP LLC, together with TCG IV LP, TCG IV-A LP, TCG IV GP LP, TCG Opportunity III LP, and TCG Opportunity III GP LP, the Reporting Entities), Tim Kutzkey and Peter Svennilson (the Reporting Individuals). The Reporting Entities and Reporting Individuals are collectively referred to as the Reporting Persons. The agreement among the Reporting Persons to file jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act is attached hereto as Exhibit 1. Each Reporting Person disclaims beneficial ownership of all securities reported in this Statement except to the extent of such Reporting Person's pecuniary interest therein, other than those securities reported herein as being held directly by such Reporting Person
    (b)
    The address of the principal offices of each Reporting Person is 1 Letterman Drive, Building D, Suite M-900, San Francisco, CA 94129.
    (c)
    Each of TCG IV LP, TCG IV-A LP and TCG Opportunity III LP is a venture capital investment entity. TCG IV GP LP is the general partner of each of TCG IV LP and TCG IV-A LP. TCG Opportunity III GP LP is the general partner of TCG Opportunity III LP. TCG Opportunity III GP LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP. Tim Kutzkey and Peter Svennilson are the managing partners of TCG IV GP LP and the managing members of TCG Opportunity III GP LLC, and are each engaged through venture capital investment entities in acquiring, holding and disposing of interests in various companies for investment purposes.
    (d)
    During the past five years, none of the Reporting Persons have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
    (e)
    None of the Reporting Persons are, nor during the last five years have been, a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (f)
    Each of TCG IV GP LP, TCG IV LP, TCG IV-A LP, TCG Opportunity III LP and TCG Opportunity III GP LP is a limited partnership organized under the laws of the State of Delaware. TCG Opportunity III GP LLC is a limited company organized under the laws of the State of Delaware. Dr. Kutzkey is a citizen of the United States of America. Mr. Svennilson is a citizen of Sweden.
    Item 3.Source and Amount of Funds or Other Consideration
     
    In September 2019, TCG IV LP purchased an aggregate of 9,670,000 shares of the Issuer's Series A Preferred Stock for a purchase price of $1.00 per share and an aggregate purchase price of approximately $9.67 million. In September 2019, TCG IV-A LP purchased an aggregate of 330,000 shares of the Issuer's Series A Preferred Stock for a purchase price of $1.00 per share and an aggregate purchase price of approximately $0.3 million. In May 2021, TCG IV LP purchased an aggregate of 10,467,526 shares of the Issuer's Series A-1 Preferred Stock for a purchase price of $2.00 per share and an aggregate purchase price of approximately $20.93 million. In May 2021, TCG IV-A LP purchased an aggregate of 357,216 shares of the Issuer's Series A-1 Preferred Stock for a purchase price of $2.00 per share and an aggregate purchase price of approximately $0.72 million. In May 2023, TCG IV LP purchased an aggregate of 827,278 shares of the Issuer's Series C Preferred Stock for a purchase price of $21.50 per share and an aggregate purchase price of approximately $17.79 million. In May 2023, TCG IV-A LP purchased an aggregate of 28,229 shares of the Issuer's Series C Preferred Stock for a purchase price of $21.50 per share and an aggregate purchase price of approximately $0.6 million. In February 2025, TCG Opp III LP purchased 5,133,076 shares of the Issuer's Series D Preferred Stock for a purchase price of $5.84 per share and an aggregate purchase price of approximately $30.0 million. In February 2026, effective upon the closing of the Issuer's initial public offering of its Common Stock (the Offering), each series of the Issuer's preferred stock automatically converted into shares of the Issuer's Common Stock on a one-for-7.4578 basis for no consideration. Following such conversion, each Reporting Person directly held such number of shares of Common Stock set forth in Item 11 of their respective Cover Pages. On February 6, 2026, in connection with the Offering, TCG IV LP purchased 1,437,323 shares of the Issuer's Common Stock for a purchase price of $18.00 per share and an aggregate purchase price of approximately $25.87 million. On February 6, 2026, in connection with the Offering, TCG IV-A LP purchased 49,556 shares of the Issuer's Common Stock for a purchase price of $18.00 per share and an aggregate purchase price of approximately $0.9 million. On February 6, 2026, in connection with the Offering, TCG Opportunity III LP purchased 630,881 shares of the Issuer's Common Stock for a purchase price of $18.00 per share and an aggregate purchase price of approximately $11.35 million. All shares of the capital stock of the Issuer purchased by TCG IV LP, TCG IV-A LP and TCG Opportunity III LP have been purchased using investment funds provided to TCG IV LP, TCG IV-A LP and TCG Opportunity III LP by its limited partner and general partner investors. Unless noted above, no part of the purchase price was borrowed by any Reporting Person for the purpose of acquiring any securities discussed in this Item 3.
    Item 4.Purpose of Transaction
     
    The information set forth in Item 3 of this Statement is incorporated herein by reference. The Reporting Persons hold the securities of the Issuer for general investment purposes. The Reporting Persons may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of Common Stock or other securities of the Issuer, dispose of any such securities, or engage in discussions with the Issuer concerning such acquisitions or dispositions or further investments in the Issuer. The Reporting Persons intend to review their investment in the Issuer on a continuing basis and, depending upon the price and availability of shares of Common Stock or other securities of the Issuer, subsequent developments affecting the Issuer, the Issuer's business and prospects, other investment and business opportunities available to the Reporting Persons, general stock market and economic conditions, tax considerations and other factors considered relevant, may decide at any time to increase or to decrease the size of their investment in the Issuer in the open market, in privately negotiated transactions, pursuant to 10b5-1 trading plans or otherwise. Except as set forth above, the Reporting Persons have no present plans or intentions which would result in or relate to any of the transactions described in subparagraphs (a) through (j) of Item 4 of Schedule 13D.
    Item 5.Interest in Securities of the Issuer
    (a)
    See Items 7-11 of the cover pages of this Statement and Item 2 above. Except to the extent of his, hers, or its pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record.
    (b)
    See Items 7-11 of the cover pages of this Statement and Item 2 above. Except to the extent of his, hers, or its pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record.
    (c)
    Except as reported in this Statement, none of the Reporting Persons has effected any transactions in the Issuer's securities within the past 60 days.
    (d)
    Under certain circumstances set forth in the limited partnership agreements of TCG IV LP, TCG IV-A LP and TCG Opportunity III LP, the general partner and limited partners of each of TCG IV LP, TCG IV-A LP and TCG Opportunity III LP may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer owned by such entity of which they are a partner.
    (e)
    Not applicable.
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    The Reporting Persons and certain of the Issuer's other investors entered into the Amended and Restated Investors' Rights Agreement, dated February 14, 2025 (the Rights Agreement). The stockholders party thereto are entitled to certain registration rights, including the right to demand that the Issuer file a registration statement or request that their shares be covered by a registration statement that the Issuer is otherwise filing. The terms and provisions of the Rights Agreement are described more fully in the Issuer's Registration Statement on Form S-1 (File No. 333-292633) and declared effective by the Commission on January 30, 2026 (the Registration Statement), and the above summary is qualified by reference to such description and the full text of the Rights Agreement, which is filed as Exhibit 2 to this Statement and is incorporated herein by reference. In connection with the Offering, each of the Reporting Persons entered into lock-up agreements, pursuant to which the Reporting Persons have agreed, subject to certain exceptions, not to sell, transfer or otherwise convey any of the Issuer's securities held by each of the Reporting Persons for 180 days following the date of the underwriting agreement for the Offering. The terms and provisions of such lock-up agreements are described more fully in the Registration Statement, and the above summary is qualified by reference to such description and the full text of the lock-up agreement, a form of which is filed as Exhibit 3 to this Statement as attached as Exhibit A to the Underwriting Agreement filed with to the Registration Statement and is incorporated herein by reference.
    Item 7.Material to be Filed as Exhibits.
     
    Exhibit 1: Joint Filing Agreement, dated February 12, 2026, by and among the Reporting Persons (filed herewith). Exhibit 2: Amended and Restated Investors' Rights Agreement, dated February 14, 2025, by and among the Registrant and certain of its stockholders, (filed as Exhibit 4.3 to the Issuer's Registration Statement on Form S-1/A as filed with the Commission on January 28, 2026 (SEC File No. 333-292633) and incorporated herein by reference). Exhibit 3: Form of Lock-Up Agreement for certain directors, officers and other stockholders of the Issuer (filed as Exhibit 1.1 to the Issuer's Registration Statement on Form S-1/A as filed with the Commission on January 28, 2026 (SEC File No. 333-292633) and incorporated herein by reference).

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Column Group IV GP, LP
     
    Signature:/s/ James Evangelista
    Name/Title:James Evangelista, Attorney-in-Fact
    Date:02/12/2026
     
    The Column Group IV, LP
     
    Signature:/s/ James Evangelista
    Name/Title:James Evangelista, Attorney-in-Fact
    Date:02/12/2026
     
    The Column Group IV-A, LP
     
    Signature:/s/ James Evangelista
    Name/Title:James Evangelista, Attorney-in-Fact
    Date:02/12/2026
     
    The Column Group Opportunity III, LP
     
    Signature:/s/ James Evangelista
    Name/Title:James Evangelista, Attorney-in-Fact
    Date:02/12/2026
     
    The Column Group Opportunity III GP, LP
     
    Signature:/s/ James Evangelista
    Name/Title:James Evangelista, Attorney-in-Fact
    Date:02/12/2026
     
    TCG Opportunity III GP, LLC
     
    Signature:/s/ James Evangelista
    Name/Title:James Evangelista, Attorney-in-Fact
    Date:02/12/2026
     
    Tim Kutzkey
     
    Signature:/s/ James Evangelista
    Name/Title:James Evangelista, as Attorney-in-Fact for Tim Kutzkey
    Date:02/12/2026
     
    Peter Svennilson
     
    Signature:/s/ James Evangelista
    Name/Title:James Evangelista, as Attorney-in-Fact for Peter Svennilson
    Date:02/12/2026
    Get the next $EIKN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EIKN

    DatePrice TargetRatingAnalyst
    3/2/2026Overweight
    Cantor Fitzgerald
    3/2/2026$32.00Overweight
    Morgan Stanley
    3/2/2026$29.00Overweight
    Analyst
    3/2/2026$26.00Outperform
    Mizuho
    3/2/2026$34.00Buy
    BofA Securities
    2/26/2026$7.00Underperform
    Wedbush
    More analyst ratings

    $EIKN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Operating Officer Klobuchar Michael A

    4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)

    3/4/26 5:04:29 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Huffines Robert Luther

    4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)

    3/4/26 5:02:00 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Frazier Kenneth C

    4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)

    3/4/26 5:01:49 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EIKN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Eikon Therapeutics

    Cantor Fitzgerald initiated coverage of Eikon Therapeutics with a rating of Overweight

    3/2/26 9:11:04 AM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Morgan Stanley initiated coverage on Eikon Therapeutics with a new price target

    Morgan Stanley initiated coverage of Eikon Therapeutics with a rating of Overweight and set a new price target of $32.00

    3/2/26 9:06:14 AM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Analyst initiated coverage on Eikon Therapeutics with a new price target

    Analyst initiated coverage of Eikon Therapeutics with a rating of Overweight and set a new price target of $29.00

    3/2/26 9:05:58 AM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EIKN
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Eikon Therapeutics Inc.

    SCHEDULE 13G - Eikon Therapeutics, Inc. (0001861123) (Subject)

    2/18/26 4:16:58 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13D filed by Eikon Therapeutics Inc.

    SCHEDULE 13D - Eikon Therapeutics, Inc. (0001861123) (Subject)

    2/12/26 6:48:54 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SCHEDULE 13G filed by Eikon Therapeutics Inc.

    SCHEDULE 13G - Eikon Therapeutics, Inc. (0001861123) (Subject)

    2/11/26 4:08:44 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $EIKN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Column Group Iv Gp, Lp converted options into 3,595,340 shares and bought $38,119,680 worth of shares (2,117,760 units at $18.00) (SEC Form 4)

    4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)

    2/9/26 9:19:00 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Foresite Capital Management Iv, Llc converted options into 4,041,687 shares and bought $999,990 worth of shares (55,555 units at $18.00) (SEC Form 4)

    4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)

    2/6/26 7:37:49 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Frazier Kenneth C bought $1,999,998 worth of shares (111,111 units at $18.00) (SEC Form 4)

    4 - Eikon Therapeutics, Inc. (0001861123) (Issuer)

    2/6/26 6:33:01 PM ET
    $EIKN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care